The Zhitong Finance App learned that on Thursday, Lilly (LLY.US) announced that it will acquire clinical-stage psychedelic drug manufacturer AtaiBeckley (ATAI.US) at a price of up to 3.8 billion US dollars. This move indicates that large pharmaceutical companies are increasingly accepting such long-stigmatized drugs as an alternative treatment for various mental illnesses. Prior to that, several psychedelic drugs had announced positive clinical trial results. In addition, in April of this year, US President Trump signed an executive order requiring the US Food and Drug Administration (FDA) to speed up the review process for such drugs, with multiple benefits continuing to fuel the popularity of the racetrack.

The Zhitong Finance App learned that on Thursday, Lilly (LLY.US) announced that it will acquire clinical-stage psychedelic drug manufacturer AtaiBeckley (ATAI.US) at a price of up to 3.8 billion US dollars. This move indicates that large pharmaceutical companies are increasingly accepting such long-stigmatized drugs as an alternative treatment for various mental illnesses. Prior to that, several psychedelic drugs had announced positive clinical trial results. In addition, in April of this year, US President Trump signed an executive order requiring the US Food and Drug Administration (FDA) to speed up the review process for such drugs, with multiple benefits continuing to fuel the popularity of the racetrack.